P473: Corticosteroid-free clinical remission rates with guselkumab maintenance therapy in patients with moderately to severely active Crohn's disease: Week 48 analyses from the phase 2 GALAXI 1 studyECCO’23 CopenhagenYear: 2023
Authors: D'Haens, G.(1)*;Afzali, A.(2);Filip, R.(3);Rolim, A.(4);Terry, N.A.(5);Salese, L.(5);Sahoo, A.(5);Frustaci, M.E.(6);Yang, Z.(6);Andrews, J.M.(7);Danese, S.(8);Hisamatsu, T.(9);
(1)Amsterdam University Medical Centers, Department of Gastroenterology, Amsterdam, The Netherlands;(2)University of Cincinnati College of Medicine and Division of Digestive Diseases, Department of Internal Medicine, Cincinnati- OH, United States;(3)University of Rzeszow, Department of Gastroenterology with IBD Unit, Rzeszow, Poland;(4)Pesquisare Saúde, Coloproctology, Santo André- São Paulo, Brazil;(5)Janssen Research and Development LLC, Immunology, Spring House- PA, United States;(6)Janssen Research and Development LLC, Statistics and Decision Sciences, Spring House- PA, United States;(7)Royal Adelaide Hospital and University of Adelaide, Department of Gastroenterology and Hepatology, Adelaide, Australia;(8)IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milano, Italy;(9)Kyorin University, Department of Gastroenterology and Hepatology, Tokyo, Japan;on behalf of the GALAXI 1 investigators
P474: Postoperative disease course after appendectomy as experimental treatment for patients with therapy refractory moderate to severe ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Reijntjes, M.(1)*;Heuthorst, L.(1);Stellingwerf, M.(1);d'Haens, G.R.(2);Bemelman, W.A.(1);Buskens, C.J.(1);
(1)Amsterdam University Medical Centers, Surgery, Amsterdam, The Netherlands;(2)Amsterdam University Medical Centers, Gastroenterology, Amsterdam, The Netherlands;
P475: Infections and malignancies during anti-TNF therapy in IBD patients affect all age groups – results from a 13-yr real-world retrospective studyECCO’23 CopenhagenYear: 2023
Authors: Majumder, S.(1,2);Melanie , L.(2);Joanne , D.(2);Naveen, S.(2);Quraishi, M.N.(2);Cooney, R.(2);Ghosh, S.(3);Iacucci, M.(1,2,4);N Shivaji, U.(1,2,4)*;
(1)University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom;(2)University Hospitals Birmingham NHS Foundation Trust, Gastroenterology, Birmingham, United Kingdom;(3)University College Cork, College of Medicine and Health- University College Cork- APC Microbiome, Cork, United Kingdom;(4)National Institute for Health Research NIHR Birmingham Biomedical Research Centre- University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom;
P476: Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programmeECCO’23 CopenhagenYear: 2023
Authors: Vermeire, S.(1)*;Yarur, A.(2);Rubin, D.T.(3);Dubinsky, M.C.(4);Regueiro, M.(5);Irving, P.(6,7);Peyrin-Biroulet, L.(8,9);Goetsch, M.(10);Gu, G.(11);Wu, J.(12);Modesto, I.(13);McDonnell, A.(14);Rabbat, C.J.(15);Green, J.(16);Anthopoulos, P.(17);
(1)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;(2)Cedars-Sinai Medical Center, Gastroenterology, Los Angeles- California, United States;(3)University of Chicago Medicine Inflammatory Bowel Disease Center, Section of Gastroenterology- Hepatology and Nutrition, Chicago- Illinois, United States;(4)Feinstein IBD Center- Mount Sinai, Gastroenterology, New York- New York, United States;(5)Cleveland Clinic, Department of Gastroenterology- Hepatology- and Nutrition, Cleveland- Ohio, United States;(6)Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(7)King's College London, School of Immunology & Microbial Sciences, London, United Kingdom;(8)University of Lorraine- Inserm- NGERE, Gastroenterology, Nancy, France;(9)Groupe Hospitalier privé Ambroise Paré - Hartmann, Paris IBD Center, Neuilly sur Seine, France;(10)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(11)Pfizer Inc, Clinical Development & Operations- Inflammation and Immunology, New York- New York, United States;(12)Pfizer Inc, Biostatistics, Groton- Connecticut, United States;(13)Pfizer Inc, Global Medical Affairs- Gastroenterology, Madrid, Spain;(14)Pfizer- Ltd, Safety Risk, Walton Oaks- Scurry, United Kingdom;(15)Pfizer Inc, Global Medical Affairs- Gastroenterology, New York- New York, United States;(16)Pfizer Inc, Field Medical- Gastroenterology, Collegeville- Pennsylvania, United States;(17)Arena Pharmaceuticals, Cardiovascular Development, San Diego- California, United States;
P477: Patient satisfaction and cost saving analysis of telemedicine in patients with inflammatory bowel disease.ECCO’23 CopenhagenYear: 2023
Authors: Bossa, F.(1)*;Carparelli, S.(1);Guerra, M.(1);Cocomazzi, F.(1);Martino, G.(1);Annese, M.(1);Nardella, M.(1);Bellucci, N.(2);Gagliardi, R.(3);Terracciano, F.(1);Pacilli, L.(4);Perri, F.(1);
(1)Fondazione Casa Sollievo della Sofferenza, Gastroenterology, San Giovanni Rotondo, Italy;(2)Fondazione Casa Sollievo della Sofferenza, Information Systems, San Giovanni Rotondo, Italy;(3)University of Foggia, Department of Economics, Foggia, Italy;(4)Fondazione Casa Sollievo della Sofferenza, Health Administration, San Giovanni Rotondo, Italy;
P479: Reliability and responsiveness of histologic disease activity indices in Crohn's DiseaseECCO’23 CopenhagenYear: 2023
Authors: Solitano, V.(1,2,3)*;Schaeffer, D.F.(4);Hogan, M.(2);Pai, R.K.(5);Zou, G.(2,6);Pai, R.K.(7);Vande Casteele, N.(8);Parker, C.E.(2);Remillard, J.(2);Christensen, B.(9,10);Panaccione, R.(2,11);Sands, B.E.(12);D'Haens, G.(2,13);Feagan, B.G.(1,2,6);Ma, C.(2,11);Jairath, V.(1,2,6);
(1)Western University, Division of Gastroenterology- Department of Medicine, London, Canada;(2)Alimentiv Inc., Medical R&D, London, Canada;(3)Humanitas University, Department of Biomedical Sciences, Milan, Italy;(4)The University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, Canada;(5)Mayo Clinic Arizona, Department of Laboratory Medicine and Pathology, Scottsdale, United States;(6)Western University, Department of Epidemiology and Biostatistics, London, Canada;(7)University of Pittsburgh School of Medicine, Department of Pathology, Pittsburgh, United States;(8)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(9)The Royal Melbourne Hospital Melbourne, Department of Gastroenterology, Parkville, Australia;(10)The University of Melbourne, Department of Medicine, Melbourne, Australia;(11)University of Calgary, Division of Gastroenterology and Hepatology- Department of Medicine, Calgary, Canada;(12)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(13)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;
P480: Ustekinumab Dose Intensification Is Effective in One-Third of Asian Inflammatory Bowel Disease Patients, Results From A Tertiary Inflammatory Bowel Disease Centre.ECCO’23 CopenhagenYear: 2023
Authors: Lim, C.T.(1)*;Tay, S.W.(1);Lim, G.H.(2);Salazar, E.(1);Ong, W.C.(3);Chan, W.P.W.(1);Tan, M.T.K.(1);
(1)Singapore General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore;(2)Singapore General Hospital, Health Services Research Unit, Singapore, Singapore;(3)Singapore General Hospital, Department of Pharmacy, Singapore, Singapore;
P481: Visceral fat to skeletal muscle area ratio predicts for Ustekinumab loss of response.ECCO’23 CopenhagenYear: 2023
Authors: Tan, Z.(1)*;Chin, A.(2);Welman, C.J.(3,4);Thin, L.W.Y.(1,5);
(1)Fiona Stanley Hospital, Gastroenterology, Murdoch, Australia;(2)Royal Perth Hospital, Gastroenterology, Perth, Australia;(3)Fiona Stanley Hospital, Medical Imaging, Murdoch, Australia;(4)Royal Perth Hospital, Radiology, Perth, Australia;(5)University of Western Australia, Internal Medicine, Perth, Australia;
P483: Golimumab response in Ulcerative Colitis as early as week 2: What can we take from this?ECCO’23 CopenhagenYear: 2023
Authors: Kumar, L.(1)*;O'Morain, N.(1);Sheridan, J.(1);Coe, C.(1);Egan, C.(1);Jones, F.(1);Cullen, G.(1);Doran, P.(2);Leyden, J.(3);Galligan, M.(2);McCarthy, J.(4);O'Toole, A.(5);Kevans, D.(6);Egan, L.(7);Doherty, G.(1);
(1)St. Vincent's University Hospital, Gastroenterology, Dublin, Ireland;(2)University College Dublin, Clinical Research, Dublin, Ireland;(3)Mater Misericordiae University Hospital, Gastroenterology, Dublin, Ireland;(4)Mercy University Hospital, Gastroenterology, Cork, Ireland;(5)Beaumont Hospital, Gastroenterology, Dublin, Ireland;(6)St. James's Hospital, Gastroenterology, Dublin, Ireland;(7)University Hospital Galway, Gastroenterology, Galway, Ireland;Investigator Network for Inflammatory Bowel Disease Therapy in Ireland (INITIative)
P484: Inflammatory Bowel Disease exercise and diet habits (IBDeat) study: chronic metabolic disease risk factors among IBD patients in New ZealandECCO’23 CopenhagenYear: 2023
Authors: Yap, J.(1)*;Wall, C.(2);Meredith-Jones, K.(1);Iosua, E.(1);Osborne, H.(1);Schultz, M.(1);
(1)University of Otago, Medicine, Dunedin, New Zealand;(2)University of Otago, Medicine, Christchurch, New Zealand;
P486: Improving enhanced recovery after surgery (ERAS): the effect of a patient-centred mobile application on patient participation in colorectal surgeryECCO’23 CopenhagenYear: 2023
Authors: Van Der Storm, S.(1)*;Jansen, M.(1);Marsman, H.A.(2);Molly, G.P.(3);Consten, E.C.(4);Groot, L.M.(4);Boer, F.C.(5);Corver, M.(5);Oosterling, S.J.(6); Tuynman, J.B.(7);Bemelman, W.A.(1);Buskens, C.J.(1);Schijven, M.P.(1);
(1)Amsterdam University Medical Center- location AMC, Surgery, Amsterdam, The Netherlands;(2)OLVG Hospital, Surgery, Amsterdam, The Netherlands;(3)OLVG, Surgery, Amsterdam, The Netherlands;(4)Meander Medical Center, Surgery, Amersfoort, The Netherlands;(5)Zaans Medical Center, Surgery, Zaandam, The Netherlands;(6)Spaarne Gasthuis Hospital, Surgery, Hoofddorp, The Netherlands;(7)Amsterdam University Medical Center- location VUmc, Surgery, Amsterdam, The Netherlands;
P488: Switch from intravenous to subcutaneous infliximab in patients with Inflammatory Bowel Disease: efficacy, safety and patients' acceptanceECCO’23 CopenhagenYear: 2023
Authors: Caballol Oliva, B.(1)*;Fernàndez-Clotet, A.(2);Panés, J.(2);Masamunt, M.C.(2);Gallego, M.(2);Barastegui, R.(2);Vara, A.(2);Giner, À.(2);Ricart, E.(2);Ordás, I.(2);
(1)Hospital Clínic i Provincial- Institut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS and CIBEREHD, Gastroenterology, Barcelona, Spain;(2)Hospital Clínic i Provincial- Institut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS- and CIBEREHD, Gastroenterology, Barcelona, Spain;
P490: Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trialsECCO’23 CopenhagenYear: 2023
Authors: Vermeire, S.(1)*;Peyrin-Biroulet, L.(2,3);Panés, J.(4);Regueiro, M.(5);Kotze, P.G.(6);Charabaty, A.(7);Goetsch, M.(8);Shan, K.(9);Wu, J.(10);McDonnell, A.(11);Woolcott, J.(12);Danese, S.(13);
(1)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;(2)University of Lorraine- Inserm- NGERE, Gastroenterology, Nancy, France;(3)Groupe Hospitalier privé Ambroise Paré - Hartmann, Paris IBD Center, Neuilly sur Seine, France;(4)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Gastroenterology, Barcelona, Spain;(5)Cleveland Clinic, Department of Digestive Disease and Surgery Institute, Cleveland- Ohio, United States;(6)Pontifícia Universidade Católica do Paraná PUCPR, Colorectal Surgery Unit, Curitiba, Brazil;(7)Johns Hopkins School of Medicine, Gastroenterology, Washington- District of Columbia, United States;(8)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(9)Pfizer- Inc, Biostatistics, New York- New York, United States;(10)Pfizer- Inc, Biostatistics, Groton- Connecticut, United States;(11)Pfizer Ltd, Safety Risk, Walton Oaks- Scurry, United Kingdom;(12)Pfizer Inc, Global Medical Affairs- Gastroenterology, Collegeville- Pennsylvania, United States;(13)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology, Milan, Italy;
P491: Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Colombel, J.F.(1)*;Irving, P.(2);Rieder, F.(3);Panaccione, R.(4);Schwartz, D.(5);Hayashi, R.(6);Zhu, X.(7);Lacerda, A.P.(8);Dubcenco, E.(8);Marced, E.(8);Hecht, P.(8);Feng, T.(8);Berg, S.(8);Reinisch, W.(9);
(1)Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, United States;(2)Guy's and St Thomas' NHS Foundation Trust, IBD Centre, London, United Kingdom;(3)Digestive Diseases and Surgery Institute- Cleveland Clinic, Department of Gastroenterology- Hepatology- & Nutrition, Cleveland, United States;(4)University of Calgary, Inflammatory Bowel Disease Unit, Calgary, Canada;(5)Vanderbilt University Medical Center, Department of Gastroenterology and Hepatology, Nashville, United States;(6)Hiroshima University Hospital, Department of Endoscopy, Hiroshima, Japan;(7)First Affiliated Hospital of Nanchang University, Departments of Gastroenterology and Hepatology, Nanchang, China;(8)AbbVie Inc., Research and Development, North Chicago, United States;(9)Medical University of Vienna, Department of Internal Medicine, Vienna, Austria;
P492: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC studyECCO’23 CopenhagenYear: 2023
Authors: Sands, B.E.(1)*;Hanauer, S.B.(2);Colombel, J.F.(3);Sandborn, W.(4);Schreiber, S.(5);Danese, S.(6);Klopocka, M.(7);Kulynych, R.(8);Kierkus, J.(9);Soltysiak, A.(10);Smolinski, P.(11);Gonciarz, M.(12);Sreckovic, S.(13);Valuyskikh, E.(14);Horynski, M.(15);Gasbarrini, A.(16);Kim, S.(17);Bae, Y.(17);Lee, S.(17);Lee, J.H.(17);Lee, J.(17);Lee, S.J.(18);Lee, S.G.(18);Kim, J.M.(18);
(1)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(2)Northwestern University/ Feinberg School of Medicine, Gastroenterology and Hepatology, Chicago- IL, United States;(3)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(4)University of California San Diego, Gastroenterology, La Jolla, United States;(5)University Hospital Schleswig Holstein, Medicine I, Kiel, Germany;(6)IRCCS San Raffaele Hospital, Gastroenterology, Milan, Italy;(7)Nicolaus Copernicus University- Collegium Medicum in Bydgoszcz, Gastroenterology and Nutrition Disorders, Bydgoszcz, Poland;(8)Zaporizhzhia regional clinical hospital, Gastroenterology and Endoscopy, Zaporizhzhia, Ukraine;(9)The Children Memorial Health Institute, Gastroenterology- Hepatology- Feeding Disorders and Pediatrics, Warsaw, Poland;(10)Centrum Medyczne Lukamed Joanna Łuka, Centrum Medyczne Lukamed Joanna Łuka, Chojnice, Poland;(11)EuroMediCare Szpital Specjalistyczny, Gastroenterology Clinical Trials, Wroclaw, Poland;(12)Military Institute of Medicine - National Research Institute, Gastroenterology and Internal Diseases, Warsaw, Poland;(13)Clinical university hospital Zvezdara, Gastroenterology and hepatology, Belgrade, Serbia;(14)LLC Novosibirskiy Gastrocenter, Clinical Research, Novosibirsk, Russian Federation;(15)Endoskopia sp. Z o.o, Gastroentrology, Sopot, Poland;(16)Dipartimento Medicina e Chirurgia Traslazionale, Dipartimento Medicina e Chirurgia Traslazionale, Roma, Italy;(17)Celltrion- Inc., Medical Science Division, Incheon, Korea- Republic Of;(18)Celltrion- Inc., Data Science Institute, Incheon, Korea- Republic Of;CT-P13
